SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '5t0g'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1QW6_A_H4BA901_1
(NITRIC-OXIDE
SYNTHASE, BRAIN)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		3 / 3 ARG R 186
VAL R 179
TRP R 184
 None
 1.14A 1qw6A-5t0gR:
undetectable		 1qw6A-5t0gR:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1QWC_A_H4BA901_1
(NITRIC-OXIDE
SYNTHASE, BRAIN)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		3 / 3 ARG R 186
VAL R 179
TRP R 184
 None
 1.21A 1qwcA-5t0gR:
undetectable		 1qwcA-5t0gR:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1S9P_B_DESB459_1
(ESTROGEN-RELATED
RECEPTOR GAMMA)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 LEU R 155
ALA R 156
LEU R   4
TYR R 143
LEU R 111
 None
 1.22A 1s9pB-5t0gR:
undetectable		 1s9pB-5t0gR:
20.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1VAG_A_H4BA901_1
(NITRIC-OXIDE
SYNTHASE, BRAIN)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		3 / 3 ARG R 186
VAL R 179
TRP R 184
 None
 1.20A 1vagA-5t0gR:
undetectable		 1vagA-5t0gR:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ZVI_A_H4BA901_1
(NITRIC-OXIDE
SYNTHASE, BRAIN)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		3 / 3 ARG R 186
VAL R 179
TRP R 184
 None
 1.23A 1zviA-5t0gR:
undetectable		 1zviA-5t0gR:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  27
LYS R  33
ALA R  46
GLY R  47
 None
 0.90A 2f16H-5t0gR:
26.8
2f16I-5t0gR:
24.1		 2f16H-5t0gR:
27.68
2f16I-5t0gR:
23.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.81A 2f16H-5t0gR:
26.8
2f16I-5t0gR:
24.1		 2f16H-5t0gR:
27.68
2f16I-5t0gR:
23.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 ALA R  20
ALA R  22
ALA R  27
VAL R  31
LYS R  33
GLY R  48
 None
 1.00A 2f16K-5t0gR:
31.8
2f16L-5t0gR:
23.8		 2f16K-5t0gR:
65.38
2f16L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
VAL R  31
LYS R  33
GLY R  47
 None
 0.98A 2f16K-5t0gR:
31.8
2f16L-5t0gR:
23.8		 2f16K-5t0gR:
65.38
2f16L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
ALA R  49
 None
 1.01A 2f16K-5t0gR:
31.8
2f16L-5t0gR:
23.8		 2f16K-5t0gR:
65.38
2f16L-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  27
LYS R  33
ALA R  46
GLY R  47
 None
 0.91A 2f16V-5t0gR:
26.8
2f16W-5t0gR:
24.1		 2f16V-5t0gR:
27.68
2f16W-5t0gR:
23.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.82A 2f16V-5t0gR:
26.8
2f16W-5t0gR:
24.1		 2f16V-5t0gR:
27.68
2f16W-5t0gR:
23.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 ALA R  20
ALA R  22
ALA R  27
VAL R  31
LYS R  33
GLY R  48
 None
 1.01A 2f16Y-5t0gR:
18.6
2f16Z-5t0gR:
23.6		 2f16Y-5t0gR:
65.38
2f16Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
VAL R  31
LYS R  33
GLY R  47
 None
 0.98A 2f16Y-5t0gR:
18.6
2f16Z-5t0gR:
23.6		 2f16Y-5t0gR:
65.38
2f16Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
ALA R  49
 None
 1.01A 2f16Y-5t0gR:
18.6
2f16Z-5t0gR:
23.6		 2f16Y-5t0gR:
65.38
2f16Z-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2V3K_A_SAMA1254_0
(ESSENTIAL FOR
MITOTIC GROWTH 1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 VAL R 138
GLY R 137
ASP R 140
LEU R   4
ALA R 159
 None
 0.91A 2v3kA-5t0gR:
undetectable		 2v3kA-5t0gR:
22.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_H_BO2H1400_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 3mg0H-5t0gR:
26.8
3mg0I-5t0gR:
24.1		 3mg0H-5t0gR:
27.68
3mg0I-5t0gR:
23.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
ALA R  27
VAL R  31
LYS R  33
ALA R  46
GLY R  47
SER R 130
 None
 0.90A 3mg0K-5t0gR:
32.0
3mg0L-5t0gR:
23.9		 3mg0K-5t0gR:
65.38
3mg0L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
VAL R  31
LYS R  33
ALA R  46
SER R 130
 None
 0.95A 3mg0K-5t0gR:
32.0
3mg0L-5t0gR:
23.9		 3mg0K-5t0gR:
65.38
3mg0L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
THR R  21
VAL R  31
LYS R  33
ALA R  46
ALA R  49
SER R 130
 None
 1.08A 3mg0K-5t0gR:
32.0
3mg0L-5t0gR:
23.9		 3mg0K-5t0gR:
65.38
3mg0L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
VAL R  31
LYS R  33
ALA R  46
GLY R  47
ALA R  49
SER R 130
 None
 0.95A 3mg0K-5t0gR:
32.0
3mg0L-5t0gR:
23.9		 3mg0K-5t0gR:
65.38
3mg0L-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  27
LYS R  33
ALA R  46
GLY R  47
 None
 0.96A 3mg0V-5t0gR:
26.9
3mg0W-5t0gR:
24.2		 3mg0V-5t0gR:
27.68
3mg0W-5t0gR:
23.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_V_BO2V1401_1
(PROTEASOME COMPONENT
PUP1
PROTEASOME COMPONENT
PUP3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 3mg0V-5t0gR:
26.9
3mg0W-5t0gR:
24.2		 3mg0V-5t0gR:
27.68
3mg0W-5t0gR:
23.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 12 ALA R  20
ALA R  22
ALA R  27
VAL R  31
LYS R  33
GLY R  48
 None
 1.03A 3mg0Y-5t0gR:
18.6
3mg0Z-5t0gR:
23.6		 3mg0Y-5t0gR:
65.38
3mg0Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		10 / 12 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
VAL R  31
LYS R  33
ALA R  46
GLY R  47
SER R 130
 None
 0.98A 3mg0Y-5t0gR:
18.6
3mg0Z-5t0gR:
23.6		 3mg0Y-5t0gR:
65.38
3mg0Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		10 / 12 THR R   1
ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
ALA R  46
GLY R  47
ALA R  49
SER R 130
 None
 1.02A 3mg0Y-5t0gR:
18.6
3mg0Z-5t0gR:
23.6		 3mg0Y-5t0gR:
65.38
3mg0Z-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 1.00A 4qvlV-5t0gR:
27.1
4qvlb-5t0gR:
27.5		 4qvlV-5t0gR:
28.33
4qvlb-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.87A 4qvlK-5t0gR:
32.2
4qvlL-5t0gR:
24.1		 4qvlK-5t0gR:
65.38
4qvlL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.86A 4qvlK-5t0gR:
32.2
4qvlL-5t0gR:
24.1		 4qvlK-5t0gR:
65.38
4qvlL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.82A 4qvlK-5t0gR:
32.2
4qvlL-5t0gR:
24.1		 4qvlK-5t0gR:
65.38
4qvlL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.97A 4qvlK-5t0gR:
32.2
4qvlL-5t0gR:
24.1		 4qvlK-5t0gR:
65.38
4qvlL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVL_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 1.00A 4qvlH-5t0gR:
25.4
4qvlN-5t0gR:
27.5		 4qvlH-5t0gR:
28.33
4qvlN-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.87A 4qvlY-5t0gR:
18.7
4qvlZ-5t0gR:
23.9		 4qvlY-5t0gR:
65.38
4qvlZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.85A 4qvlY-5t0gR:
18.7
4qvlZ-5t0gR:
23.9		 4qvlY-5t0gR:
65.38
4qvlZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.83A 4qvlY-5t0gR:
18.7
4qvlZ-5t0gR:
23.9		 4qvlY-5t0gR:
65.38
4qvlZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.97A 4qvlY-5t0gR:
18.7
4qvlZ-5t0gR:
23.9		 4qvlY-5t0gR:
65.38
4qvlZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.86A 4qvmK-5t0gR:
32.4
4qvmL-5t0gR:
24.1		 4qvmK-5t0gR:
64.90
4qvmL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 9 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.84A 4qvmK-5t0gR:
32.4
4qvmL-5t0gR:
24.1		 4qvmK-5t0gR:
64.90
4qvmL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.80A 4qvmK-5t0gR:
32.4
4qvmL-5t0gR:
24.1		 4qvmK-5t0gR:
64.90
4qvmL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.94A 4qvmK-5t0gR:
32.4
4qvmL-5t0gR:
24.1		 4qvmK-5t0gR:
64.90
4qvmL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVM_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 0.99A 4qvmH-5t0gR:
25.6
4qvmN-5t0gR:
27.6		 4qvmH-5t0gR:
28.33
4qvmN-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.85A 4qvmY-5t0gR:
24.6
4qvmZ-5t0gR:
23.9		 4qvmY-5t0gR:
64.90
4qvmZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.83A 4qvmY-5t0gR:
24.6
4qvmZ-5t0gR:
23.9		 4qvmY-5t0gR:
64.90
4qvmZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.81A 4qvmY-5t0gR:
24.6
4qvmZ-5t0gR:
23.9		 4qvmY-5t0gR:
64.90
4qvmZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.95A 4qvmY-5t0gR:
24.6
4qvmZ-5t0gR:
23.9		 4qvmY-5t0gR:
64.90
4qvmZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.88A 4qvnK-5t0gR:
32.2
4qvnL-5t0gR:
24.0		 4qvnK-5t0gR:
64.90
4qvnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.88A 4qvnK-5t0gR:
32.2
4qvnL-5t0gR:
24.0		 4qvnK-5t0gR:
64.90
4qvnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.79A 4qvnK-5t0gR:
32.2
4qvnL-5t0gR:
24.0		 4qvnK-5t0gR:
64.90
4qvnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.96A 4qvnK-5t0gR:
32.2
4qvnL-5t0gR:
24.0		 4qvnK-5t0gR:
64.90
4qvnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.88A 4qvnY-5t0gR:
18.8
4qvnZ-5t0gR:
23.8		 4qvnY-5t0gR:
64.90
4qvnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.88A 4qvnY-5t0gR:
18.8
4qvnZ-5t0gR:
23.8		 4qvnY-5t0gR:
64.90
4qvnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.79A 4qvnY-5t0gR:
18.8
4qvnZ-5t0gR:
23.8		 4qvnY-5t0gR:
64.90
4qvnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.97A 4qvnY-5t0gR:
18.8
4qvnZ-5t0gR:
23.8		 4qvnY-5t0gR:
64.90
4qvnZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVP_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 4qvpH-5t0gR:
25.4
4qvpI-5t0gR:
24.2		 4qvpH-5t0gR:
28.33
4qvpI-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.89A 4qvpK-5t0gR:
32.3
4qvpL-5t0gR:
23.7		 4qvpK-5t0gR:
64.90
4qvpL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.88A 4qvpK-5t0gR:
32.3
4qvpL-5t0gR:
23.7		 4qvpK-5t0gR:
64.90
4qvpL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.81A 4qvpK-5t0gR:
32.3
4qvpL-5t0gR:
23.7		 4qvpK-5t0gR:
64.90
4qvpL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.98A 4qvpK-5t0gR:
32.3
4qvpL-5t0gR:
23.7		 4qvpK-5t0gR:
64.90
4qvpL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVP_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 4qvpV-5t0gR:
27.0
4qvpW-5t0gR:
24.2		 4qvpV-5t0gR:
28.33
4qvpW-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.88A 4qvpY-5t0gR:
24.6
4qvpZ-5t0gR:
23.8		 4qvpY-5t0gR:
64.90
4qvpZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.88A 4qvpY-5t0gR:
24.6
4qvpZ-5t0gR:
23.8		 4qvpY-5t0gR:
64.90
4qvpZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.81A 4qvpY-5t0gR:
24.6
4qvpZ-5t0gR:
23.8		 4qvpY-5t0gR:
64.90
4qvpZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.98A 4qvpY-5t0gR:
24.6
4qvpZ-5t0gR:
23.8		 4qvpY-5t0gR:
64.90
4qvpZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.91A 4qvqK-5t0gR:
32.2
4qvqL-5t0gR:
24.0		 4qvqK-5t0gR:
64.90
4qvqL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.91A 4qvqK-5t0gR:
32.2
4qvqL-5t0gR:
24.0		 4qvqK-5t0gR:
64.90
4qvqL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.81A 4qvqK-5t0gR:
32.2
4qvqL-5t0gR:
24.0		 4qvqK-5t0gR:
64.90
4qvqL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.99A 4qvqK-5t0gR:
32.2
4qvqL-5t0gR:
24.0		 4qvqK-5t0gR:
64.90
4qvqL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.91A 4qvqY-5t0gR:
24.5
4qvqZ-5t0gR:
23.8		 4qvqY-5t0gR:
64.90
4qvqZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.91A 4qvqY-5t0gR:
24.5
4qvqZ-5t0gR:
23.8		 4qvqY-5t0gR:
64.90
4qvqZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.82A 4qvqY-5t0gR:
24.5
4qvqZ-5t0gR:
23.8		 4qvqY-5t0gR:
64.90
4qvqZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.99A 4qvqY-5t0gR:
24.5
4qvqZ-5t0gR:
23.8		 4qvqY-5t0gR:
64.90
4qvqZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.87A 4qvvH-5t0gR:
25.6		 4qvvH-5t0gR:
28.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		4 / 8 THR R   1
LYS R  33
GLY R  47
GLY R  48
 None
 0.75A 4qvvK-5t0gR:
32.5
4qvvL-5t0gR:
24.1		 4qvvK-5t0gR:
64.90
4qvvL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVV_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.86A 4qvvV-5t0gR:
27.2		 4qvvV-5t0gR:
28.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		4 / 8 THR R   1
LYS R  33
GLY R  47
GLY R  48
 None
 0.75A 4qvvY-5t0gR:
24.7
4qvvZ-5t0gR:
23.9		 4qvvY-5t0gR:
64.90
4qvvZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVW_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 1.03A 4qvwV-5t0gR:
27.1
4qvwb-5t0gR:
27.6		 4qvwV-5t0gR:
28.33
4qvwb-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.88A 4qvwK-5t0gR:
32.4
4qvwL-5t0gR:
24.0		 4qvwK-5t0gR:
64.90
4qvwL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
 None
 0.92A 4qvwK-5t0gR:
32.4
4qvwL-5t0gR:
24.0		 4qvwK-5t0gR:
64.90
4qvwL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.82A 4qvwK-5t0gR:
32.4
4qvwL-5t0gR:
24.0		 4qvwK-5t0gR:
64.90
4qvwL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVW_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 1.03A 4qvwH-5t0gR:
25.5
4qvwN-5t0gR:
27.6		 4qvwH-5t0gR:
28.33
4qvwN-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.88A 4qvwY-5t0gR:
24.6
4qvwZ-5t0gR:
23.9		 4qvwY-5t0gR:
64.90
4qvwZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
 None
 0.92A 4qvwY-5t0gR:
24.6
4qvwZ-5t0gR:
23.9		 4qvwY-5t0gR:
64.90
4qvwZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.81A 4qvwY-5t0gR:
24.6
4qvwZ-5t0gR:
23.9		 4qvwY-5t0gR:
64.90
4qvwZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVY_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.91A 4qvyH-5t0gR:
25.6		 4qvyH-5t0gR:
28.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
 None
 1.04A 4qvyK-5t0gR:
32.4
4qvyL-5t0gR:
24.1		 4qvyK-5t0gR:
64.90
4qvyL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
ALA R  22
VAL R  31
LYS R  33
GLY R  48
 None
 1.04A 4qvyK-5t0gR:
32.4
4qvyL-5t0gR:
24.1		 4qvyK-5t0gR:
64.90
4qvyL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
VAL R  31
LYS R  33
 None
 0.99A 4qvyK-5t0gR:
32.4
4qvyL-5t0gR:
24.1		 4qvyK-5t0gR:
64.90
4qvyL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QVY_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.91A 4qvyV-5t0gR:
27.2
4qvyW-5t0gR:
24.2		 4qvyV-5t0gR:
28.33
4qvyW-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
 None
 1.03A 4qvyY-5t0gR:
24.6
4qvyZ-5t0gR:
23.9		 4qvyY-5t0gR:
64.90
4qvyZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
ALA R  22
VAL R  31
LYS R  33
GLY R  48
 None
 1.02A 4qvyY-5t0gR:
24.6
4qvyZ-5t0gR:
23.9		 4qvyY-5t0gR:
64.90
4qvyZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 10 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
VAL R  31
LYS R  33
 None
 0.98A 4qvyY-5t0gR:
24.6
4qvyZ-5t0gR:
23.9		 4qvyY-5t0gR:
64.90
4qvyZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 0.99A 4qw0V-5t0gR:
27.2
4qw0b-5t0gR:
27.7		 4qw0V-5t0gR:
28.33
4qw0b-5t0gR:
27.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.85A 4qw0H-5t0gR:
25.6
4qw0I-5t0gR:
24.2		 4qw0H-5t0gR:
28.33
4qw0I-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 7 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
 None
 0.94A 4qw0K-5t0gR:
32.6		 4qw0K-5t0gR:
64.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 0.98A 4qw0H-5t0gR:
25.6
4qw0N-5t0gR:
27.6		 4qw0H-5t0gR:
28.33
4qw0N-5t0gR:
27.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW0_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.85A 4qw0V-5t0gR:
27.2
4qw0W-5t0gR:
24.2		 4qw0V-5t0gR:
28.33
4qw0W-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 7 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
 None
 0.96A 4qw0Y-5t0gR:
24.7		 4qw0Y-5t0gR:
64.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW1_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.86A 4qw1H-5t0gR:
25.4
4qw1I-5t0gR:
24.1		 4qw1H-5t0gR:
28.33
4qw1I-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.86A 4qw1K-5t0gR:
32.2
4qw1L-5t0gR:
24.0		 4qw1K-5t0gR:
64.90
4qw1L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.86A 4qw1K-5t0gR:
32.2
4qw1L-5t0gR:
24.0		 4qw1K-5t0gR:
64.90
4qw1L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.80A 4qw1K-5t0gR:
32.2
4qw1L-5t0gR:
24.0		 4qw1K-5t0gR:
64.90
4qw1L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.98A 4qw1K-5t0gR:
32.2
4qw1L-5t0gR:
24.0		 4qw1K-5t0gR:
64.90
4qw1L-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QW1_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.86A 4qw1V-5t0gR:
27.0
4qw1W-5t0gR:
24.2		 4qw1V-5t0gR:
28.33
4qw1W-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.87A 4qw1Y-5t0gR:
18.8
4qw1Z-5t0gR:
23.8		 4qw1Y-5t0gR:
64.90
4qw1Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.86A 4qw1Y-5t0gR:
18.8
4qw1Z-5t0gR:
23.8		 4qw1Y-5t0gR:
64.90
4qw1Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.79A 4qw1Y-5t0gR:
18.8
4qw1Z-5t0gR:
23.8		 4qw1Y-5t0gR:
64.90
4qw1Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.99A 4qw1Y-5t0gR:
18.8
4qw1Z-5t0gR:
23.8		 4qw1Y-5t0gR:
64.90
4qw1Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.85A 4qw3K-5t0gR:
32.4
4qw3L-5t0gR:
24.0		 4qw3K-5t0gR:
64.90
4qw3L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.81A 4qw3K-5t0gR:
32.4
4qw3L-5t0gR:
24.0		 4qw3K-5t0gR:
64.90
4qw3L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.78A 4qw3K-5t0gR:
32.4
4qw3L-5t0gR:
24.0		 4qw3K-5t0gR:
64.90
4qw3L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.94A 4qw3K-5t0gR:
32.4
4qw3L-5t0gR:
24.0		 4qw3K-5t0gR:
64.90
4qw3L-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.85A 4qw3Y-5t0gR:
24.7
4qw3Z-5t0gR:
23.8		 4qw3Y-5t0gR:
64.90
4qw3Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.83A 4qw3Y-5t0gR:
24.7
4qw3Z-5t0gR:
23.8		 4qw3Y-5t0gR:
64.90
4qw3Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.78A 4qw3Y-5t0gR:
24.7
4qw3Z-5t0gR:
23.8		 4qw3Y-5t0gR:
64.90
4qw3Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.95A 4qw3Y-5t0gR:
24.7
4qw3Z-5t0gR:
23.8		 4qw3Y-5t0gR:
64.90
4qw3Z-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.90A 4qwuK-5t0gR:
31.4
4qwuL-5t0gR:
23.7		 4qwuK-5t0gR:
64.90
4qwuL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
THR R  21
ALA R  27
LYS R  33
MET R  45
 None
 1.00A 4qwuK-5t0gR:
31.4
4qwuL-5t0gR:
23.7		 4qwuK-5t0gR:
64.90
4qwuL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.92A 4qwuY-5t0gR:
18.7
4qwuZ-5t0gR:
23.8		 4qwuY-5t0gR:
64.90
4qwuZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 THR R   1
THR R  21
ALA R  27
LYS R  33
MET R  45
 None
 0.97A 4qwuY-5t0gR:
18.7
4qwuZ-5t0gR:
23.8		 4qwuY-5t0gR:
64.90
4qwuZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.85A 5bxnK-5t0gR:
32.2
5bxnL-5t0gR:
23.7		 5bxnK-5t0gR:
65.38
5bxnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.83A 5bxnK-5t0gR:
32.2
5bxnL-5t0gR:
23.7		 5bxnK-5t0gR:
65.38
5bxnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.82A 5bxnK-5t0gR:
32.2
5bxnL-5t0gR:
23.7		 5bxnK-5t0gR:
65.38
5bxnL-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.97A 5bxnK-5t0gR:
32.2
5bxnL-5t0gR:
23.7		 5bxnK-5t0gR:
65.38
5bxnL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BXN_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.83A 5bxnV-5t0gR:
26.9
5bxnW-5t0gR:
24.3		 5bxnV-5t0gR:
27.90
5bxnW-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  27
LYS R  33
GLY R  47
 None
 0.85A 5bxnY-5t0gR:
18.7
5bxnZ-5t0gR:
23.8		 5bxnY-5t0gR:
65.38
5bxnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.83A 5bxnY-5t0gR:
18.7
5bxnZ-5t0gR:
23.8		 5bxnY-5t0gR:
65.38
5bxnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
ALA R  27
LYS R  33
 None
 0.82A 5bxnY-5t0gR:
18.7
5bxnZ-5t0gR:
23.8		 5bxnY-5t0gR:
65.38
5bxnZ-5t0gR:
22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.97A 5bxnY-5t0gR:
18.7
5bxnZ-5t0gR:
23.8		 5bxnY-5t0gR:
65.38
5bxnZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CZ7_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.86A 5cz7V-5t0gR:
27.2
5cz7W-5t0gR:
24.3		 5cz7V-5t0gR:
28.33
5cz7W-5t0gR:
23.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 1.02A 5d0xV-5t0gR:
27.2
5d0xb-5t0gR:
27.6		 5d0xV-5t0gR:
28.33
5d0xb-5t0gR:
27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.63A 5d0xK-5t0gR:
32.3
5d0xL-5t0gR:
24.1		 5d0xK-5t0gR:
51.71
5d0xL-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
THR R  21
LYS R  33
GLY R  47
ALA R  49
 None
 0.98A 5d0xH-5t0gR:
25.6
5d0xN-5t0gR:
27.6		 5d0xH-5t0gR:
28.33
5d0xN-5t0gR:
27.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5D0X_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.88A 5d0xV-5t0gR:
27.2		 5d0xV-5t0gR:
28.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5D0X_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.64A 5d0xY-5t0gR:
24.6
5d0xZ-5t0gR:
23.9		 5d0xY-5t0gR:
51.71
5d0xZ-5t0gR:
22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5DQY_A_BEZA401_0
(THIOREDOXIN)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		4 / 8 ILE R  13
LYS R   7
VAL R  14
CYH R 102
 None
 1.07A 5dqyA-5t0gR:
undetectable		 5dqyA-5t0gR:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5F_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 5l5fH-5t0gR:
25.5
5l5fI-5t0gR:
24.2		 5l5fH-5t0gR:
28.33
5l5fI-5t0gR:
23.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5F_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.84A 5l5fV-5t0gR:
27.2
5l5fW-5t0gR:
24.3		 5l5fV-5t0gR:
28.33
5l5fW-5t0gR:
23.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.82A 5l5zH-5t0gR:
25.5
5l5zI-5t0gR:
24.4		 5l5zH-5t0gR:
28.33
5l5zI-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 ALA R  20
ALA R  22
ALA R  27
LYS R  33
GLY R  48
 None
 0.97A 5l5zK-5t0gR:
33.3
5l5zL-5t0gR:
23.9		 5l5zK-5t0gR:
83.09
5l5zL-5t0gR:
21.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 9 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
LYS R  33
GLY R  47
ALA R  49
 None
 1.05A 5l5zK-5t0gR:
33.3
5l5zL-5t0gR:
23.9		 5l5zK-5t0gR:
83.09
5l5zL-5t0gR:
21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.82A 5l5zV-5t0gR:
27.2
5l5zW-5t0gR:
24.3		 5l5zV-5t0gR:
28.33
5l5zW-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 9 ALA R  20
ALA R  22
ALA R  27
LYS R  33
GLY R  48
 None
 0.97A 5l5zY-5t0gR:
33.3
5l5zZ-5t0gR:
23.9		 5l5zY-5t0gR:
83.09
5l5zZ-5t0gR:
21.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 9 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
LYS R  33
GLY R  47
ALA R  49
 None
 1.05A 5l5zY-5t0gR:
33.3
5l5zZ-5t0gR:
23.9		 5l5zY-5t0gR:
83.09
5l5zZ-5t0gR:
21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_H_BO2H301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.83A 5l66H-5t0gR:
25.5
5l66I-5t0gR:
24.3		 5l66H-5t0gR:
28.33
5l66I-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.78A 5l66K-5t0gR:
32.7
5l66L-5t0gR:
24.1		 5l66K-5t0gR:
67.15
5l66L-5t0gR:
21.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.91A 5l66K-5t0gR:
32.7
5l66L-5t0gR:
24.1		 5l66K-5t0gR:
67.15
5l66L-5t0gR:
21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L66_V_BO2V301_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.82A 5l66V-5t0gR:
27.1
5l66W-5t0gR:
24.3		 5l66V-5t0gR:
28.33
5l66W-5t0gR:
23.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
LYS R  33
GLY R  47
ALA R  49
 None
 0.78A 5l66Y-5t0gR:
32.7
5l66Z-5t0gR:
23.9		 5l66Y-5t0gR:
67.15
5l66Z-5t0gR:
21.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
THR R  21
LYS R  33
ALA R  49
 None
 0.91A 5l66Y-5t0gR:
32.7
5l66Z-5t0gR:
23.9		 5l66Y-5t0gR:
67.15
5l66Z-5t0gR:
21.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_H_BO2H306_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 10 THR R   1
ALA R  20
ALA R  46
GLY R  47
ALA R  49
 None
 0.94A 5lf3H-5t0gR:
27.5
5lf3I-5t0gR:
24.2		 5lf3H-5t0gR:
27.31
5lf3I-5t0gR:
20.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 ALA R  20
ALA R  22
LYS R  33
GLY R  47
GLY R  48
ALA R  49
TYR R 169
 None
 0.76A 5lf3K-5t0gR:
33.4
5lf3L-5t0gR:
24.7		 5lf3K-5t0gR:
100.00
5lf3L-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 ALA R  20
THR R  21
ALA R  22
LYS R  33
ALA R  49
TYR R 169
 None
 0.95A 5lf3K-5t0gR:
33.4
5lf3L-5t0gR:
24.7		 5lf3K-5t0gR:
100.00
5lf3L-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 ALA R  20
THR R  21
ALA R  22
LYS R  33
GLY R  47
TYR R 169
 None
 1.17A 5lf3K-5t0gR:
33.4
5lf3L-5t0gR:
24.7		 5lf3K-5t0gR:
100.00
5lf3L-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.98A 5lf3K-5t0gR:
33.4
5lf3L-5t0gR:
24.7		 5lf3K-5t0gR:
100.00
5lf3L-5t0gR:
23.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_V_BO2V303_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 10 THR R   1
ALA R  20
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.93A 5lf3V-5t0gR:
27.5
5lf3W-5t0gR:
24.2		 5lf3V-5t0gR:
27.31
5lf3W-5t0gR:
20.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 ALA R  20
ALA R  22
LYS R  33
GLY R  47
GLY R  48
ALA R  49
TYR R 169
 None
 0.77A 5lf3Y-5t0gR:
33.3
5lf3Z-5t0gR:
24.7		 5lf3Y-5t0gR:
100.00
5lf3Z-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 ALA R  20
THR R  21
ALA R  22
LYS R  33
ALA R  49
TYR R 169
 None
 0.95A 5lf3Y-5t0gR:
33.3
5lf3Z-5t0gR:
24.7		 5lf3Y-5t0gR:
100.00
5lf3Z-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 ALA R  20
THR R  21
ALA R  22
LYS R  33
GLY R  47
TYR R 169
 None
 1.17A 5lf3Y-5t0gR:
33.3
5lf3Z-5t0gR:
24.7		 5lf3Y-5t0gR:
100.00
5lf3Z-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 0.98A 5lf3Y-5t0gR:
33.3
5lf3Z-5t0gR:
24.7		 5lf3Y-5t0gR:
100.00
5lf3Z-5t0gR:
23.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_H_6V8H305_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  46
GLY R  47
ALA R  49
 None
 0.92A 5lf7H-5t0gR:
27.5
5lf7I-5t0gR:
24.2		 5lf7H-5t0gR:
27.31
5lf7I-5t0gR:
20.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
ALA R  22
VAL R  31
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 1.10A 5lf7K-5t0gR:
33.3
5lf7L-5t0gR:
24.8		 5lf7K-5t0gR:
100.00
5lf7L-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
 None
 1.33A 5lf7K-5t0gR:
33.3
5lf7L-5t0gR:
24.8		 5lf7K-5t0gR:
100.00
5lf7L-5t0gR:
23.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_V_6V8V303_0
(PROTEASOME SUBUNIT
BETA TYPE-3
PROTEASOME SUBUNIT
BETA TYPE-7)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  20
ALA R  46
GLY R  47
ALA R  49
 None
 0.89A 5lf7V-5t0gR:
27.5
5lf7W-5t0gR:
24.2		 5lf7V-5t0gR:
27.31
5lf7W-5t0gR:
20.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		8 / 11 THR R   1
ALA R  20
ALA R  22
VAL R  31
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 1.11A 5lf7Y-5t0gR:
33.2
5lf7Z-5t0gR:
24.8		 5lf7Y-5t0gR:
100.00
5lf7Z-5t0gR:
23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
VAL R  31
LYS R  33
GLY R  47
 None
 1.31A 5lf7Y-5t0gR:
33.2
5lf7Z-5t0gR:
24.8		 5lf7Y-5t0gR:
100.00
5lf7Z-5t0gR:
23.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_H_BO2H301_0
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
ALA R  27
LYS R  33
ALA R  46
GLY R  47
 None
 1.01A 6hwdH-5t0gR:
25.4
6hwdI-5t0gR:
24.2		 6hwdH-5t0gR:
18.97
6hwdI-5t0gR:
14.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_H_BO2H301_0
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-3)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 12 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.93A 6hwdH-5t0gR:
25.4
6hwdI-5t0gR:
24.2		 6hwdH-5t0gR:
18.97
6hwdI-5t0gR:
14.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
ALA R  22
ALA R  27
LYS R  33
GLY R  47
 None
 0.94A 6hwdK-5t0gR:
31.8
6hwdL-5t0gR:
24.0		 6hwdK-5t0gR:
78.75
6hwdL-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 THR R   1
ALA R  20
ALA R  22
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 1.00A 6hwdK-5t0gR:
31.8
6hwdL-5t0gR:
24.0		 6hwdK-5t0gR:
78.75
6hwdL-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
LYS R  33
 None
 1.00A 6hwdK-5t0gR:
31.8
6hwdL-5t0gR:
24.0		 6hwdK-5t0gR:
78.75
6hwdL-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
ALA R  49
 None
 1.08A 6hwdK-5t0gR:
31.8
6hwdL-5t0gR:
24.0		 6hwdK-5t0gR:
78.75
6hwdL-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
GLY R  47
 None
 1.22A 6hwdK-5t0gR:
31.8
6hwdL-5t0gR:
24.0		 6hwdK-5t0gR:
78.75
6hwdL-5t0gR:
16.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_V_BO2V301_0
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
ALA R  27
LYS R  33
ALA R  46
GLY R  47
 None
 1.02A 6hwdV-5t0gR:
26.9		 6hwdV-5t0gR:
18.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HWD_V_BO2V301_0
(PROTEASOME SUBUNIT
BETA TYPE-2)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		5 / 11 THR R   1
LYS R  33
ALA R  46
GLY R  47
ALA R  49
 None
 0.92A 6hwdV-5t0gR:
26.9		 6hwdV-5t0gR:
18.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
ALA R  22
ALA R  27
LYS R  33
GLY R  47
 None
 0.95A 6hwdY-5t0gR:
18.7
6hwdZ-5t0gR:
23.8		 6hwdY-5t0gR:
78.75
6hwdZ-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		7 / 11 THR R   1
ALA R  20
ALA R  22
LYS R  33
GLY R  47
GLY R  48
ALA R  49
 None
 1.00A 6hwdY-5t0gR:
18.7
6hwdZ-5t0gR:
23.8		 6hwdY-5t0gR:
78.75
6hwdZ-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
ALA R  27
LYS R  33
 None
 1.00A 6hwdY-5t0gR:
18.7
6hwdZ-5t0gR:
23.8		 6hwdY-5t0gR:
78.75
6hwdZ-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
ALA R  49
 None
 1.08A 6hwdY-5t0gR:
18.7
6hwdZ-5t0gR:
23.8		 6hwdY-5t0gR:
78.75
6hwdZ-5t0gR:
16.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 5t0g PROTEASOME SUBUNIT
BETA TYPE-5
(Homo
sapiens) 		6 / 11 THR R   1
ALA R  20
THR R  21
ALA R  22
LYS R  33
GLY R  47
 None
 1.22A 6hwdY-5t0gR:
18.7
6hwdZ-5t0gR:
23.8		 6hwdY-5t0gR:
78.75
6hwdZ-5t0gR:
16.53